Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2019 Earnings Conference Call - Final Transcript
Mar 05, 2020 • 08:30 am ET
Ladies and gentlemen, thank you for standing by, and welcome to the fourth-quarter 2019 Syros Pharmaceuticals, Inc. earnings conference call. [Operator instructions] It is now my pleasure to introduce vice president of corporate communications and investor relations, Naomi Aoki.
Thank you. This morning, we issued a press release with our fourth-quarter and full-year 2019 financial results, along with anticipated future milestones and recent accomplishments. This release is available on the Investors and Media section of Syros' website at www.syros.com. We will begin the call with prepared remarks by Dr.
Nancy Simonian, our chief executive officer; and Joe Ferra, our chief financial officer. We'll then open the call for question. Dr. David Roth, our chief medical officer; Dr. Eric Olson, our chief scientific officer; and Dr. Jeremy Springhorn, our chief business officer, are also on the call and will be available for Q&A. Before we begin, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our annual report on Form 10-K that we filed this morning, and any other filings that we may make with the SEC in the future.
In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. I would now like to turn the call over to Nancy.
Thank you, Naomi. Good morning, everyone, and thank you for joining us today. At Syros, we are redefining the power of small molecules to control the expression of genes, with the aim of delivery medicines that provide a profound benefit to currently underserved patients with cancer and monogenic diseases. In 2019, we made important progress toward this goal.
We continue to advance our lead program, SY-1425, a first-in-class selective RAR alpha agonist, currently in a Phase 2 trial, presenting promising clinical data in newly diagnosed unfit RARA-positive AML patients and initiating a trial cohort in relapsed or refractory RARA-positive AML patients. We continue to build on our leadership in selective CDK7 inhibition, prioritizing the development of SY-5609, our highly selective and potent oral CDK7 inhibitor, which is now in a Phase 1 trial in patients with select solid tumors. And we entered into a collaboration with global blood therapeutics to expand our effort in sickle cell disease and beta thalassemia with the aim of accelerating the development of novel oral medicines that could provide a functional cure for patients with these diseases. Together, these accomplishments provide a tremendous foundation as we enter 2020.
We expect this year to be important for Syros, marked by continued clinical execution and culminating in meaningful data readouts in both 1425 and 5609 in the fourth quarter. In